PRIMARY OBJECTIVES:
I. To assess feasibility of pre-operative stereotactic body radiotherapy (SBRT) in prostate cancer patients at high risk for recurrence after prostatectomy.
SECONDARY OBJECTIVES:
I. To assess safety and acute toxicity of SBRT followed by prostatectomy. This will be based on Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 and patient reported quality of life (Expanded Prostate Cancer Index Composite \[EPIC\] and International Prostate Symptom Score \[IPSS\] questionnaires).
II. Investigation of the radiobiology of SBRT in prostate cancer using resected prostate tumor tissue.
III. Evaluation of the nature of the immune response to prostate cancer generated by SBRT.
OUTLINE:
Patients undergo 3 fractions of SBRT over 1-2 weeks, 2-4 weeks prior to radical prostatectomy.
After completion of the study treatment, patients are followed up at 0 to 4 weeks, and every 3 months for 1 year.
